Key result
Implantation of Supraflex sirolimus-eluting stents in real-world patients resulted in an 11% rate of major adverse cardiovascular and cerebrovascular events at 1-year follow-up.
Why the study?
There is little information on the outcomes of Indian patients treated with drug-eluting stents.
Observational (n=100)
No
Supraflex sirolimus-eluting stents demonstrated an 11% rate of MACCE at 1 year in a real-world Indian cohort, with diabetes, hypertension, kidney dysfunction, and LV function identified as significant predictors of adverse outcomes.
Acceptable 1-year MACCE with Supraflex in Indian patients; leaves open generalizability beyond this observational cohort.
Background: The development of a sirolimus-eluting coronary stent (SES) was a big step forward in interventional cardiology. SES has been demonstrated in large, randomized clinical studies to reduce angiographic restenosis and target vessel revascularization (TVR) when compared to bare-metal stents and other drug-eluting stents (DESs). However, there is little information on the outcomes of Indian patients treated with Drug-eluting stents (DES). As a result, the study's goal was to assess the efficacy of Supraflex sirolimus-eluting coronary stents in the treatment of coronary artery disease and to identify severe adverse cardiovascular and cerebrovascular events. Methods: This single-center, observational, nonrandomized study enrolled unselected real-world patients at a tertiary care center who had undergone implantation with Supraflex sirolimus-eluting stents. The primary endpoint of the study was major adverse cardiovascular and cerebrovascular events (MACCE), which is a conglomeration of cardiac death, target lesion revascularization, TVR, cerebrovascular accident (CVA), and heart failure at 1-year follow-up. Results: A total of 100 patients were intervened successfully with sirolimus-eluting stents. Out of total patients, diabetes and hypertension were observed in 38% and 35% of patients, respectively. According to the American College of Cardiology/American Heart Association classification, there were 68% of type B lesions and 32% of type C lesions. At 1-year follow-up, major adverse cardiovascular events were 11%, a composite of 4% target lesion revascularization, 3% target vessel revascularization, 1% CVA, and 5% heart failure. Diabetes ( P = 0.02), hypertension ( P = 0.01), kidney dysfunction ( P = 0.002), and left ventricular (LV) function ( P = 0.01) strongly correlated with outcome (MACCE). Conclusion: There was an acceptable rate of adverse events after implantation of the Supraflex sirolimus-eluting stents, although slightly higher than in other studies. Diabetes, hypertension, kidney dysfunction, and LV function strongly correlate with the outcome (MACCE).
No takes yet. Share an insight, caveat, or question.
Singh et al. (2022) conducted an observational in Coronary artery disease (n=100). Supraflex sirolimus-eluting stents was evaluated on Major adverse cardiovascular and cerebrovascular events (MACCE). Implantation of Supraflex sirolimus-eluting stents in real-world patients resulted in an 11% rate of major adverse cardiovascular and cerebrovascular events at 1-year follow-up.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: